Constellation Brands vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Victor NY Mexican beer imports (NYSE: STZ) ~$9.8B FY2025 revenue; Modelo Especial #1 US beer brand since June 2023, Corona/Pacifico, wine portfolio review, competing with ABI and Molson Coors.
About
Constellation Brands, Inc. is a Victor, New York-based beer, wine, and spirits company — publicly traded on the New York Stock Exchange (NYSE: STZ) as an S&P 500 Consumer Staples component — producing and marketing the United States rights to Mexican beer brands including Modelo Especial, Corona Extra, Pacifico, and Modelo Negra (acquired from Anheuser-Busch InBev as a condition of ABI's 2013 Grupo Modelo acquisition), and a wine and spirits portfolio including Robert Mondavi, Kim Crawford, The Prisoner, Meiomi, and High West whiskey through approximately 10,000 employees. In fiscal year 2025 (ending February 2025), Constellation Brands reported revenues of approximately $9.8 billion, with the Beer Division (Modelo, Corona, Pacifico) generating approximately $8.4 billion (+4-5% organic growth) as Modelo Especial maintained its status as the #1-selling beer in the United States by dollar sales — a position Modelo captured from Bud Light in June 2023 following the Bud Light controversy and has held since. CEO Bill Newlands retired in 2024, with Garth Hankinson succeeding him, maintaining Constellation's strategy of investing behind the Modelo brand family's premium Hispanic-heritage positioning as the fastest-growing segment of US beer consumers (Hispanic adult beer drinkers choosing culturally authentic imported Mexican lagers over domestic brands). The Wine and Spirits segment faced significant headwinds from premiumization-to-value trading and market share pressure — Constellation announced a strategic review of the Wine and Spirits portfolio in 2024, exploring potential divestitures to focus capital exclusively on the Beer Division's high-margin, high-growth beer brands.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.